We are live on ! Find out more
STAB

Statera Biopharma, Inc. Common Stock
STAB

Delisted

STAB was delisted on the 11th of January, 2023.

Back to rankings

16 hedge funds and large institutions have $1.03M invested in Statera Biopharma, Inc. Common Stock in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

7% more funds holding

Funds holding: 15 → 16 (+1)

18% less capital invested

Capital invested by funds: $1.26M → $1.03M (-$230K)

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.36%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
5
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$27.5K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.85K
3
UBS Group
UBS Group
Switzerland
+$1.47K
4
BlackRock
BlackRock
New York
+$1.24K
5
Bank of America
Bank of America
North Carolina
+$328

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$38K

STAB Hedge Fund Activity: Q3 2018 in Review

16 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q3 2018, worth a combined $1.03M — down 18% from $1.26M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new STAB positions and 1 closed out — a net gain of 1 holder — while 5 added to existing stakes and 0 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $27.5K. The largest seller was Citadel Advisors, exiting entirely with an estimated $38K sold.

  • 16 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q3 2018, up from 15 in Q2 2018.
  • Funds reported $1.03M of Statera Biopharma, Inc. Common Stock stock for Q3 2018, down 18% quarter-over-quarter.
  • 2 funds opened new Statera Biopharma, Inc. Common Stock positions in Q3 2018 and 1 closed out, a net change of +1 holder.
  • The largest Statera Biopharma, Inc. Common Stock buyer in Q3 2018 was Renaissance Technologies, an estimated $27.5K added.
  • The largest Statera Biopharma, Inc. Common Stock seller in Q3 2018 was Citadel Advisors, an estimated $38K sold.

Based on aggregated 13F filings for Q3 2018.